Development of small-molecule inhibitors of sphingosine-1-phosphate signaling

作者：Edmonds Yvette; Milstien Sheldon; Spiegel Sarah^*

来源：Pharmacology & Therapeutics, 2011, 132(3): 352-360.

DOI：10.1016/j.pharmthera.2011.08.004

• Sphingosine-1-phosphate
• Sphingosine kinase
• Inhibitors
• Antagonists
• Cancer
• Multiple sclerosis
• Asthma
• Rheumatoid arthritis
• Inflammatory bowel disease
• Sepsis

The pleiotropic sphingolipid mediator, sphingosine-1-phosphate, produced in cells by two sphingosine kinase isoenzymes, SphK1 and SphK2, regulates many cellular and physiological processes important for homeostasis and development and pathophysiology. Many of the actions of S1P are mediated by a family of five specific cell surface receptors that are ubiquitously and specifically expressed, although important direct intracellular targets of SIP have also recently been identified. SIP. SphK1, and or S1P receptors have been linked to onset and progression of numerous diseases, including many types of cancer, and especially inflammatory disorders, such as multiple sclerosis, asthma, rheumatoid arthritis, inflammatory bowel disease, and sepsis. SIP formation and signaling are attractive targets for development of new therapeutics. The effects of a number of inhibitors of SphKs and S1PRs have been examined in animal models of human diseases. The effectiveness of the immunosuppressant FTY720 (known as Fingolimod or Gilenya), recently approved for the treatment of multiple sclerosis, whose actions are mediated by downregulation of S1PR1, has become the gold standard for S1P-centric drugs. Here, we review SIP biology and signaling with an emphasis on potential therapeutic benefits of specific interventions and discuss recent development of small molecule antagonists and agonists that target specific subtypes of SIP receptors as well as inhibitors of SphKs.

• 出版日期2011-12